Senores Pharmaceuticals
+24.94% revenue YoY
Q2 FY2027 · Period ended 30 Sep 2026
Basis: Consolidated, unaudited
Reported revenue (₹ crore, except EPS in ₹/share): 192.33
Read summary and comparison caveats
Senores Pharmaceuticals' September-quarter revenue rose 24.94% year on year to ₹192.33 crore. Profit attributable to equity holders was ₹39.49 crore, up 21.96% year on year. The defined operating EBITDA margin was 29.98%, compared with 27.08% a year earlier.
- The group acquired 75% of Apnar Pharma on 16 Jan 2026 and consolidated it from acquisition; year-on-year comparisons therefore include a changed group perimeter.
- Source: consolidated statement, PDF page 5. Values are ₹ crore, except reported basic EPS in ₹ per share; EPS is not annualised.
- Year ago is the quarter ended 30 Sep 2025; previous quarter is 30 Jun 2026. Changes use reported statement values; EPS changes use reported rounded EPS.
- EBITDA is computed as profit before tax plus finance costs plus depreciation and amortisation minus other income. Margin is this measure divided by revenue from operations.
- Equity-holder profit of ₹39.49 crore is higher than total consolidated PAT of ₹36.60 crore because non-controlling interests recorded a ₹2.89 crore loss. The same attribution basis is used for comparisons.
- Detected through RSS and separately checked against the original statement. Raw notice timestamp has no supplied timezone suffix; this is selected checked coverage.
Checked 29 Oct 2026
Open original filing